You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Small Molecule MYC Degraders as Novel Cancer Therapeutic Agents

    SBC: Stemsynergy Therapeutic            Topic: 102

    PROJECT SUMMARY/ABSTRACT The MYC family proteins are comprised of three paralogs termed c-myc, N-myc, and L-myc. The MYC proteins play a fundamental role in cell proliferation and oncogenesis by regulating cellular processes such as gene transcription, protein translation, cell cycle progression, and cell death. While N-myc and L-myc drive oncogenesis in a small number of cancer types, the require ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension

    SBC: AQUALUNG THERAPEUTICS, CORP            Topic: NHLBI

    ABSTRACT Pulmonary arterial hypertension (PAH) is a fatal disease (without curative therapies) that is critically influenced by dysregulated inflammatory pathways. This A1 R42 Fast Track STTR application focuses on eNAMPT (extra- cellular nicotinamide phosphoribosyltransferase) as a novel, highly attractive PAH target. Aqualung Therapeutics has developed a humanized eNAMPT-neutralizing mAb, ALT-10 ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Ultrasound Stimulated Chondrogenic Stem Cell Therapy for Osteoarthritis

    SBC: LAB TO PHARMACY, LLC            Topic: NIAMS

    Abstract Osteoarthritis (OA) is the most common degenerative disease in the musculoskeletal system. While it can affect any joint, hip, and knee, OA carries an enormous burden of pain and reduced mobility. Despite decades of research, there are currently no clinically effective treatments that can repair damaged cartilage or halt the progression of this disease. However, recent advances in tissue ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Inter-alpha Inhibitors in Experimental Necrotizing Enterocolitis

    SBC: PROTHERA BIOLOGICS, INC.            Topic: NICHD

    Necrotizing enterocolitis (NEC) is a devastating acute inflammatory condition of the gastrointestinal tract resulting in intestinal necrosis, systemic sepsis and multi-system organ failure found mostly in infants born prematurely. Despite modern medical advances in the past decade, the etiology remains elusive and morbidity and mortality are still unacceptably high. It has been concluded that the ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Development of an electrical impedance myography (EIM) vaginal device for the evaluation of pelvic skeletal muscles

    SBC: BOLD TYPE LLC            Topic: NICHD

    1 Abstract2 Bold Type is developing the “SenseWand”, a wireless pelvic floor diagnostic system (device and app)3 to evaluate pelvic floor muscle health using electrical impedance myography (EIM). PFDs are complex4 conditions (e.g. pelvic organ prolapse, stress urinary incontinence, high tone pelvic floor dysfunction) that impact5 millions of women worldwide. It is estimated that PFDs will affe ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Digital Uroflowmetry for Office and Home

    SBC: UROGENIE LLC            Topic: 400

    Abstract Uroflowmetry is the most common urodynamic test performed by urologists to assess the function of the lower urinary tract. This simple non-invasive study measures urinary flow rates and when summarized graphically offers insights into various types of lower urinary tract symptoms. Current systems call upon a patient to void into a commode with a funnel to direct the flow of urine into a v ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. A nanosized magnetic particle system for fast and efficient neuronal extracellular vesicle enrichment from plasma

    SBC: CAPTIS DIAGNOSTICS            Topic: R

    SUMMARY/Abstract Extracellular vesicles (EVs) are nanovesicles, which contain surface markers, and cell- and cell-state-specific cargo of their tissue (and cell) of origin, reflecting the tissue or cell’s physiological state. Most importantly, neuronal EVs can pass the blood-brain barrier (BBB) into blood circulation and provide a new approach of gaining direct access to brain pathogenic process ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Development of an Oscillated Insertion tool to Eliminate Surgically Induced Neurodegeneration for Optical Neuroimaging of Cognitive Aging and Dementia

    SBC: ACTUATED MEDICAL, INC.            Topic: NIA

    This Phase I SBIR develops a system for gentle and accurate insertion of large optical neuroscience probes (e.g., GRIN lenses) to improve outcomes in aging research. Additionally, the project supports Qingguang Zhang. Ph.D. through the NIA Research and Entrepreneurial Development Immersion (REDI) program at a small business. Entrepreneurial development activities for his project will include proje ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury

    SBC: PROTHERA BIOLOGICS, INC.            Topic: 105

    Perinatal brain injury resulting in mental retardation and cerebral palsy is the most severe disability in children and affects 40-148 in preterm and 1–2/1000 in full term infants. This places a huge burden on society, emphasizing the critical need for improved prevention/treatment strategies to decrease perinatal brain injury. Hypothermia (HT) is the only FDA approved therapy to attenuate brain ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Wearable Wireless Respiratory Monitoring System that Detects and Predicts Opioid Induced Respiratory Depression

    SBC: RTM Vital Signs, LLC            Topic: NIDA

    PROJECT SUMMARY. Opioids are the most prescribed drug in US hospitals, and opioid induced respiratory depression (OIRD) is a widespread and life-threatening problem. Episodes of OIRD on the general hospital floor are common, occurring in up to 46% of patients. Despite the prevalence of this problem, OIRD has yet to be effectively addressed through monitoring technology. There is great clinical nee ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government